Story perspectives

FDA Approves First New Motion Sickness Drug in 40 Years

12/31/2025

27 6

Summary

Story summary

The U.S. Food and Drug Administration approved Vanda Pharmaceuticals' Nereus (tradipitant) to prevent motion-induced vomiting, the first new treatment in over 40 years.
The approval followed two late-stage studies involving 681 patients that showed significant reductions in vomiting.
The FDA imposed a clinical hold on the drug, which was lifted in December 2024.
Vanda licensed tradipitant from Eli Lilly in 2012 and has explored its use for other conditions.

1 of 1

Story summary

The U.S. Food and Drug Administration approved Vanda Pharmaceuticals' Nereus (tradipitant) to prevent motion-induced vomiting, the first new treatment in over 40 years.
The approval followed two late-stage studies involving 681 patients that showed significant reductions in vomiting.
The FDA imposed a clinical hold on the drug, which was lifted in December 2024.
Vanda licensed tradipitant from Eli Lilly in 2012 and has explored its use for other conditions.